Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ISIS 329993 in paroxysmal atrial fibrillation
2012-000833-38Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- May 2012
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2 trial of ISIS-329993 in Atrial fibrillation (AFib), sponsored by Ionis Pharmaceuticals. Primary endpoint: Atrial fibrillation burden. Started May 2012; status: completed.
02
Drugs
ISIS-329993
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2012-000833-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000833-38.